Participate in a Clinical Trial
Participating in a clinical trial is a great way to contribute to curing, preventing, and treating type 1 diabetes (T1D) and its complications. Learn more below about the clinical trials currently recruiting in your area as well as Breakthrough T1D's easy tool to match you with a clinical trial in 60 seconds.
Choosing to participate in a T1D clinical trial is a very personal decision, but one that can have a significant impact on curing, preventing and treating T1D. There are many opportunities in the <chapter area> to participate in a T1D clinical trial close to home. See below for active opportunities.
Additionally, Breakthrough T1D has an easy-to-use tool called the Clinical Trials Connection where you can match with a clinical trial in 60 seconds. It asks users some simple questions about themselves before matching them with trials for which they are eligible. Clinical Trials Connection uses your city, distance you’re willing to travel and other characteristics to narrow down hundreds of trials to the ones in which you might be interested. Start your search by visiting breakthrought1d.org/impact/research/clinical-trials today!
If you have any questions, please contact our North Carolina Clinical Trials Education Volunteers Natasha Bolick or Thomas Kern.
Updated: January 16, 2025
FEATURED T1D STUDIES IN TRIANGLE
North Carolina
Developing the Resilient, Empowered, Active Living with Diabetes for Families (REAL‑Fam)
Researchers are seeking caregivers of children with Type 1 Diabetes, individuals living with Type 1 Diabetes, and healthcare providers to participate in a 60–90 minute virtual focus group. Participants will receive a $25 gift card.
Questions: Email Dr. Vanessa Jewell at vanessa_jewell@med.unc.edu
https://www.med.unc.edu/healthsciences/diabetes/
CureGN Diabetes
CureGN is a large multi‑center, long‑term study of patients with diabetes who also have nephrotic syndrome or other glomerular diseases.
Able to participate:
- Type 1 or Type 2 Diabetes
- One of these kidney diseases: MCD, FSGS, MN, IgAN
- At least 18 years old
https://researchforme.unc.edu/index.php/en/study-details?rcid=3282
IACT in T1D Participants (Eating Disorders + T1D)
Evaluating a mobile‑health intervention for individuals living with Type 1 Diabetes and an eating disorder.
Location: Durham, NC
Able to participate: Ages 16–50, T1D, eating disorder diagnosis
https://clinicaltrials.gov/study/NCT05540704
ZONE Study (ZT‑01 for Night‑Time Hypoglycemia)
Testing whether ZT‑01 can reduce night‑time low blood sugars in adults with long‑standing T1D.
Location: Morehead City, NC
Able to participate: Ages 18–75, T1D ≥5 years, A1C ≤10, at risk for night‑time lows
https://clinicaltrials.gov/study/NCT05762107
Fabulinus (Frexalimab for Newly Diagnosed T1D)
Evaluating whether Frexalimab can preserve pancreatic beta‑cell function in newly diagnosed T1D.
Location: Chapel Hill, NC
Able to participate: Ages 12–35, newly diagnosed T1D
https://clinicaltrials.gov/study/NCT06111586
CATT1 (Cadisegliatin as Adjunct Therapy)
Phase 3 trial of cadisegliatin as an add‑on therapy to insulin in adults with T1D.
Locations: Chapel Hill & Morehead City, NC
Able to participate: Ages 18+, T1D
https://clinicaltrials.gov/study/NCT06334133
CHARGE‑UP (Reducing Diabetes Distress)
Behavioral approaches to reduce diabetes distress in adults with T1D or LADA.
Location: Chapel Hill, NC
Able to participate: Ages 30+, T1D or LADA, experiencing diabetes distress
https://clinicaltrials.gov/study/NCT06405373
Stage 2 T1D Registry (TZIELD Follow‑Up)
Collecting information from individuals with Stage 2 T1D who received TZIELD.
Location: Chapel Hill, NC
Able to participate: Stage 2 T1D, TZIELD treatment
https://clinicaltrials.gov/study/NCT06481904
CNP‑103 in Recent T1D
Evaluating CNP‑103 to preserve natural insulin production in recently diagnosed T1D.
Locations: Greenville, Raleigh, Smithfield, NC
Able to participate: Ages 12–35, Stage 3 T1D diagnosed within 6 months
https://clinicaltrials.gov/study/NCT06783309
HLA Demographics in T1D Adults
Studying the HLA‑DRB1*04:01 genotype in adults with T1D.
Location: Chapel Hill, NC
Able to participate: Ages 18–45, T1D
https://clinicaltrials.gov/study/NCT06860516
SUPRASS‑T1D‑1 (Tirzepatide for T1D + Obesity)
Evaluating tirzepatide vs. placebo in adults with T1D and overweight/obesity.
Location: Morehead City, NC
Able to participate: Ages 18+, T1D, overweight or obese
https://clinicaltrials.gov/study/NCT06914895
POLARIS (GNTI‑122 Cell Therapy)
Studying a personalized cell therapy made from a participant’s own blood cells to preserve insulin production.
Locations: Chapel Hill & Durham, NC
Able to participate: Ages 18–45, T1D diagnosis within 120 days
https://clinicaltrials.gov/study/NCT0691935
SUPRASS‑T1D‑2 (Long‑Term Tirzepatide Study)
Long‑term evaluation of tirzepatide in adults with T1D and overweight/obesity.
Location: Chapel Hill, NC
Able to participate: Ages 18+, T1D, overweight or obese
https://clinicaltrials.gov/study/NCT06962280
Orforglipron (Weight‑Loss Study, No Diabetes Required)
Evaluating orforglipron for weight reduction in adults without diabetes.
Locations: Chapel Hill, Charlotte, Fayetteville, NC
Able to participate: Overweight or obese, no diabetes
https://clinicaltrials.gov/study/NCT06972459 (
ONWARDS 11 (Once‑Weekly Insulin Icodec)
Comparing once‑weekly insulin icodec to once‑daily insulin glargine.
Locations: Greenville, Morehead City, New Bern, Wilmington, NC
Able to participate: Adults with T1D using insulin injections
https://clinicaltrials.gov/study/NCT07076199
Beta Preserve (Teplizumab for Newly Diagnosed T1D)
Evaluating teplizumab vs. placebo in children and young adults newly diagnosed with Stage 3 T1D.
Location: Asheville, NC
Able to participate: Ages 1–25, Stage 3 T1D
https://clinicaltrials.gov/study/NCT07088068
JAKPOT T1D (Preserving Insulin Production)
TrialNet study testing treatments to preserve insulin production in newly diagnosed T1D. Travel assistance may be available.
Able to participate: Ages 12–35, T1D ≤3 months, A1C <10
https://www.trialnet.org/our-research/newly-diagnosed-t1d/jakpot-t1d
TrialNet Risk Screening (T1D Antibody Screening)
Screening for T1D‑related autoantibodies in people with a relative living with T1D.
Location: Virtual or NC
Able to participate: Ages 2–45, must have a T1D relative
https://www.trialnet.org/our-research/risk-screening
Virtual
UP‑CBT (Telemedicine‑Delivered Unified Protocol for CBT)
Evaluating a telemedicine‑delivered CBT protocol enhanced with CGM review to address anxiety, depression, and glycemic control in young adults with T1D.
Able to participate:
- Ages 18–35
- T1D for >6 months
- A1C 7.5–14%
- Anxiety or depressive mood disorder
Contact: Dr. Todd Farchione — tfarchio@bu.edu
Gratitude Journaling Study (Adolescents with T1D)
8‑week study evaluating the effect of gratitude journaling on psychological and glycemic outcomes. Participants complete journaling and surveys before and after the intervention. Compensation: $50.
Able to participate:
- Ages 12–17
- T1D ≥6 months
- English‑speaking
- Internet access
Contact: Dr. Rebecca Koerner — rkoerner1@usf.edu
Resources
What Are Clinical Trials Video
Match To Clinical Trials in 60 Seconds
Breakthrough T1D and Clinical Trials
Meet Your CTEVs: Natasha Bolick
Natasha Bolick is a longtime supporter of Breakthrough T1D (formerly JDRF). She is very familiar with the hardships of T1D’s; her mom, sister, and grandmother were all T1D. Everyone in the house knew how to give shots, check glucose levels, and where the sugar was stored in the event of a low. Her family inspired her to become a biomedical engineer to help ease medical burdens and improve quality of life. She holds Bachelor’s and Master’s degrees in Biomedical Engineering from NC State University and University of New South Wales, respectively, a MBA from Duke University, and certifications as a Project Manager (PMP) and Clinical Trial Researcher (CCRP). Natasha has spent a good portion of her career in diabetes research and clinical trials for drug delivery devices. With 25 years’ experience in medical devices, today Natasha is a Director of Innovation at BD Technologies & Innovation (Durham, NC), leading a team developing new medical products to advance healthcare. She is involved with her local Breakthrough T1D NC Triangle chapter as a board member and their Clinical Trial Education Volunteer. She is excited about supporting such an amazing cause to help find a T1D cure and make T1D lives easier until then!
Meet Your CTEVs: Thomas Kern
Tom, a member of the Breakthrough T1D Piedmont Triad Board, was diagnosed with type 1 diabetes at age 8, 37 years ago. His dad was diagnosed in his mid-50s (originally, he was mis-diagnosed as a Type 2). Tom’s younger daughter, Jocelyn, was diagnosed at age 7 (via TrialNet, while she was still in Stage 2, before she needed insulin). Tom and his wife, Amy, got Jocelyn into a post-clinical trial of ATG, with Dr. Michael Haller at the University of Florida, more than six years ago and—although she wears a CGM—Jocelyn has still not progressed to Stage 3/insulin-dependence.